ONCY

Oncolytics Biotech Inc

Add to Watchlist

Advanced Chart

0.860

-0.007(-0.807%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.8749

Open

0.830

VWAP

0.86

Vol

531.02K

Mkt Cap

76.17M

Low

0.830

Amount

454.47K

EV/EBITDA(TTM)

Total Shares

75.42M

90.05M

EV/OCF(TTM)

P/S(TTM)

Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Get winning stock picks in minutes

4 Analyst Rating

351.01% Upside

Wall Street analysts forecast ONCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCY is 3.88 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

351.01% Upside

Current: 0.860

Low

3.00

Averages

3.88

High

5.00

351.01% Upside

Current: 0.860

Low

3.00

Averages

3.88

High

5.00

JonesResearch

Soumit Roy

Buy

Hold

downgrade

2025-05-16

Reason

JonesResearch

Soumit Roy

Price Target

2025-05-16

downgrade

Buy

Hold

Reason

JonesResearch analyst Soumit Roy downgraded Oncolytics to Hold from Buy without a price target. The company is continuing to actively search for a Chief Executive Officer, as well as exploring potential business development opportunities, the analyst tells investors in a research note. The firm says it needs to get a better understanding on Oncolytics' path forward "as there is an immediate need for capital."

RBC Capital

Douglas Miehm

Buy

Maintains

$6 → $5

2025-03-10

Reason

RBC Capital

Douglas Miehm

Price Target

$6 → $5

2025-03-10

Maintains

Buy

Reason

RBC Capital lowered the firm's price target on Oncolytics to C$5 from C$6 and keeps an Outperform rating on the shares.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

2025-03-10

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

2025-03-10

Reiterates

Strong Buy

Reason

Maxim Group

Jason McCarthy

Strong Buy

Maintains

$5 → $3

2025-03-10

Reason

Maxim Group

Jason McCarthy

Price Target

$5 → $3

2025-03-10

Maintains

Strong Buy

Reason

Maxim lowered the firm's price target on Oncolytics to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model to reflect the expected dilution from the company needing to raise capital in the near-term to fund its cancer programs, the analyst tells investors in a research note. Maxim adds however that it remains positive on the opportunities for Oncolytics in pela in breast and pancreatic cancer.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

2025-02-03

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

2025-02-03

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

2024-11-14

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

2024-11-14

Reiterates

Strong Buy

Reason

See All Ratings

Get winning stock picks in minutes

Valuation Metrics

The current forward P/E ratio for Oncolytics Biotech Inc (ONCY.O) is -3.63, compared to its 5-year average forward P/E of -4.70. For a more detailed relative valuation and DCF analysis to assess Oncolytics Biotech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.70

Current PE

-3.63

Overvalued PE

-2.82

Undervalued PE

-6.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.71

Current EV/EBITDA

-1.86

Overvalued EV/EBITDA

-1.19

Undervalued EV/EBITDA

-4.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

21.69

Current PS

0.00

Overvalued PS

62.66

Undervalued PS

-19.28